Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. The study saw 114 healthy adults inoculated with the virus and then ...

Enanta Pharmaceuticals’ respiratory syncytial virus (RSV) antiviral reduced the viral load in a phase 2 study in children, maintaining hopes the biotech can find a niche in a market now dominated by ...

Living with HIV comes with unique health challenges, but advances in treatment have transformed it into a manageable chronic ...

The decrease in CD4 cells during HIV infection seems to be driven by immune activation, which does not always correlate with viral load. Experienced clinicians are all too familiar with the ...

Living with HIV means becoming fluent in a language of numbers that might seem confusing at first but actually hold the key to your health and future. Two numbers in particular – your viral load and ...

According to the U.S. Centers for Disease Control and Prevention (CDC) and other sources, there are approximately 1.2 million people living with HIV in the United States, and another 1.2 to 2.2 ...

Fluctuations in circulating hepatitis C virus RNA could be "clinically meaningful" in a substantial number of patients with chronic infection, and could influence the best time to prescribe antiviral ...

Next-day HIV viral load testing results do not significantly improve linkage to treatment or prevention care for adults at risk for acquisition or people with HIV not receiving daily antiretroviral ...

Who gets sick? Much of COVID-19’s prevalence, severity, and lethality may have to do with viral particles you are exposed to—the issue of viral load, also called viral dose. Not much is written on ...